Onesource Specialty Pharma delivered a strong Q4 FY26 recovery with revenue of ₹428.2 crore (up 47% QoQ) and EBITDA of ₹91.9 crore (up >5x QoQ), driven by the start of commercia...
✓ Verified against BSE filing
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
The proposed scheme to acquire Ster Science injectables business was deferred due to valuation concerns from a long tail of smaller investors, despite majority support.
medium · management_commentaryRevenue growth relies on customers obtaining regulatory approvals in various markets; delays could impact sequential improvement.
medium · analyst_questionNew lines must be qualified and validated on time; any delays could constrain ability to meet robust demand.
medium · data_observationOral GLP-1 formulations could capture up to a third of the market, potentially reducing demand for injectable formulations.
low · analyst_question